We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

16 hedge funds and large institutions have $35.3M invested in GT Biopharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.87% more ownership

Funds ownership: 50.01% → 55.87% (+5.9%)

6% less funds holding

Funds holding: 17 → 16 (-1)

7% less capital invested

Capital invested by funds: $38.1M → $35.3M (-$2.82M)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$422K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.21K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21.2K
2
UBS Group
UBS Group
Switzerland
-$12.1K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.27K
4
BlackRock
BlackRock
New York
-$74
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$5
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$35.1M +$422K +176,509 +18%
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$63K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$34.5K +$9.21K +3,857 +34%
Vanguard Group
4
Vanguard Group
Pennsylvania
$24.1K – – –
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$23.1K -$21.2K -8,879 -47%
Wells Fargo
6
Wells Fargo
California
$23.1K – – –
BlackRock
7
BlackRock
New York
$22.5K -$74 -31 -0.3%
UBS Group
8
UBS Group
Switzerland
$9.01K -$12.1K -5,078 -57%
TRCT
9
Tower Research Capital (TRC)
New York
$3.79K -$1.27K -530 -24%
Morgan Stanley
10
Morgan Stanley
New York
$614 – – –
Bank of America
11
Bank of America
North Carolina
$62 – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$28 – – –
BBPWM
13
Blue Bell Private Wealth Management
Pennsylvania
$23 – – –
BNP Paribas Financial Markets
14
BNP Paribas Financial Markets
France
$14 – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$2 – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– -$5 -2 -29%
FRA
17
Front Row Advisors
California
– -$3 -1 Closed

GTBP Hedge Fund Activity: Q3 2024 in Review

16 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2024, worth a combined $35.3M — down 7.4% from $38.1M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GTBP and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.

The largest buyer was DekaBank Deutsche Girozentrale, adding an estimated $422K. The largest seller was Susquehanna International Group, cutting an estimated $21.2K.

  • 16 institutional investors held GT Biopharma (GTBP) as of Q3 2024, down from 17 in Q2 2024.
  • Funds reported $35.3M of GT Biopharma stock for Q3 2024, down 7.4% quarter-over-quarter.
  • 0 funds opened new GT Biopharma positions in Q3 2024 and 1 closed out, a net change of -1 holder.
  • The largest GT Biopharma buyer in Q3 2024 was DekaBank Deutsche Girozentrale, an estimated $422K added.
  • The largest GT Biopharma seller in Q3 2024 was Susquehanna International Group, an estimated $21.2K sold.

Based on aggregated 13F filings for Q3 2024.